Q2 2025 Zymeworks Inc Earnings Call Transcript
Key Points
- Zymeworks Inc (ZYME) reported a significant increase in total revenue to $48.7 million in Q2 2025, up from $19.2 million in Q2 2024, driven by milestone payments and royalty revenues.
- The company achieved IND clearance for its second ADC candidate, CW2251, targeting hepatocellular carcinoma, marking progress in its clinical pipeline.
- Zymeworks Inc (ZYME) has a strong cash position with $333.4 million in cash resources, expected to fund operations into the second half of 2027.
- The company has multiple strategic partnerships, including with Jazz Pharmaceuticals and B1 Medicines, which have resulted in milestone payments and expanded international patient access.
- Zymeworks Inc (ZYME) is advancing a diversified pipeline with several candidates in clinical and preclinical stages, demonstrating consistent execution across R&D programs.
- Operating expenses for Q2 2025 were $49.4 million, representing a decrease from the previous year but still a significant expenditure.
- The company faces risks and uncertainties typical of its industry and stage of development, which could impact future performance.
- There is a reliance on partnerships for revenue generation, which may be subject to external factors and timelines beyond the company's control.
- The anticipated Horizon GEA study results have been guided to Q4 2025, which may be perceived as a delay by some investors.
- Zymeworks Inc (ZYME) has not completed a public equity offering in 3.5 years, which could limit access to additional capital if needed.
Thank you for standing by.
This is the conference operator.
Welcome to Zam Works, 2nd quarter, 2025 results conference call and webcast. As a reminder.
All participants are in listen-only mode and the conference is being recorded.
After the presentation, there will be an opportunity to ask questions. To ask a question, please press 11 on your telephone keypad.
I would now like to turn the conference over to Channel and Amer, senior director of Investor Relations. Please go ahead.
Thank you operator, and good afternoon, everyone. Thanks for joining our 2nd quarter of 2025 results conference call.
Before we begin, I'd like to remind you that we will be making a number of 4 different statements during this call, including without limitation, those 4 different statements identified in our slides and the accompanying oral commentary.
Auditing statements are based upon our current expectations and various assumptions and are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
